| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Loneliness | 6 | 2011 | 25 | 0.970 |
Why?
|
| Health Surveys | 8 | 2015 | 239 | 0.820 |
Why?
|
| Health Status | 6 | 2015 | 368 | 0.730 |
Why?
|
| Quinidine | 5 | 2012 | 11 | 0.620 |
Why?
|
| Dextromethorphan | 5 | 2012 | 11 | 0.610 |
Why?
|
| Sleep | 4 | 2015 | 447 | 0.580 |
Why?
|
| Mortality | 3 | 2005 | 150 | 0.490 |
Why?
|
| Diabetic Neuropathies | 2 | 2012 | 41 | 0.380 |
Why?
|
| Depressive Disorder | 3 | 2010 | 223 | 0.370 |
Why?
|
| Middle Aged | 54 | 2018 | 25699 | 0.360 |
Why?
|
| Social Isolation | 1 | 2010 | 67 | 0.350 |
Why?
|
| Analgesics, Opioid | 3 | 2006 | 436 | 0.350 |
Why?
|
| Depression | 5 | 2011 | 499 | 0.350 |
Why?
|
| Male | 72 | 2018 | 42012 | 0.350 |
Why?
|
| Physician-Patient Relations | 2 | 2005 | 622 | 0.340 |
Why?
|
| Exercise Test | 4 | 2010 | 165 | 0.340 |
Why?
|
| Aged | 44 | 2018 | 18932 | 0.330 |
Why?
|
| Exercise Tolerance | 3 | 2005 | 52 | 0.330 |
Why?
|
| Interpersonal Relations | 1 | 2010 | 174 | 0.330 |
Why?
|
| Female | 63 | 2018 | 45759 | 0.320 |
Why?
|
| Pseudobulbar Palsy | 2 | 2004 | 2 | 0.310 |
Why?
|
| Humans | 102 | 2018 | 88611 | 0.310 |
Why?
|
| Adult | 49 | 2018 | 26348 | 0.290 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 4 | 2001 | 94 | 0.290 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2010 | 187 | 0.290 |
Why?
|
| Multiple Sclerosis | 3 | 2010 | 269 | 0.280 |
Why?
|
| Actigraphy | 3 | 2015 | 58 | 0.280 |
Why?
|
| Logistic Models | 6 | 2015 | 1205 | 0.280 |
Why?
|
| Time Factors | 15 | 2018 | 5319 | 0.280 |
Why?
|
| Health Services Accessibility | 2 | 2018 | 418 | 0.270 |
Why?
|
| Laughter | 2 | 2006 | 4 | 0.270 |
Why?
|
| Crying | 2 | 2006 | 6 | 0.270 |
Why?
|
| Risk Factors | 16 | 2015 | 5449 | 0.270 |
Why?
|
| Cross-Sectional Studies | 7 | 2015 | 1694 | 0.270 |
Why?
|
| Neuropsychological Tests | 2 | 2004 | 507 | 0.260 |
Why?
|
| Longitudinal Studies | 7 | 2015 | 1051 | 0.260 |
Why?
|
| Physical Fitness | 1 | 2005 | 51 | 0.250 |
Why?
|
| Physician Incentive Plans | 1 | 2005 | 20 | 0.250 |
Why?
|
| Azathioprine | 1 | 2005 | 125 | 0.250 |
Why?
|
| United States | 15 | 2015 | 6882 | 0.240 |
Why?
|
| Disclosure | 1 | 2005 | 109 | 0.240 |
Why?
|
| Trust | 1 | 2005 | 97 | 0.240 |
Why?
|
| Cesarean Section | 2 | 1997 | 140 | 0.230 |
Why?
|
| Social Support | 4 | 2010 | 204 | 0.230 |
Why?
|
| Anesthesia, Obstetrical | 2 | 1994 | 28 | 0.230 |
Why?
|
| Aging | 4 | 2014 | 712 | 0.220 |
Why?
|
| Anesthesia, Epidural | 2 | 1994 | 32 | 0.220 |
Why?
|
| Patient Participation | 1 | 2005 | 224 | 0.220 |
Why?
|
| Morphine | 3 | 2002 | 130 | 0.220 |
Why?
|
| Immunosuppressive Agents | 2 | 2005 | 994 | 0.220 |
Why?
|
| Aged, 80 and over | 20 | 2018 | 6723 | 0.210 |
Why?
|
| Morbidity | 1 | 2003 | 149 | 0.210 |
Why?
|
| Social Class | 1 | 2003 | 134 | 0.210 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 460 | 0.200 |
Why?
|
| Breast Feeding | 2 | 2005 | 98 | 0.200 |
Why?
|
| Intraoperative Complications | 3 | 1994 | 188 | 0.200 |
Why?
|
| Translating | 1 | 2001 | 18 | 0.200 |
Why?
|
| Crohn Disease | 2 | 2005 | 749 | 0.200 |
Why?
|
| Health Maintenance Organizations | 1 | 2001 | 20 | 0.200 |
Why?
|
| Communication Barriers | 1 | 2001 | 29 | 0.200 |
Why?
|
| Models, Psychological | 3 | 2011 | 158 | 0.190 |
Why?
|
| Emotions | 1 | 2004 | 349 | 0.190 |
Why?
|
| Intervertebral Disc | 3 | 1989 | 16 | 0.190 |
Why?
|
| Age Factors | 9 | 2016 | 1863 | 0.180 |
Why?
|
| Double-Blind Method | 15 | 2012 | 1716 | 0.180 |
Why?
|
| Acute Kidney Injury | 2 | 1994 | 308 | 0.170 |
Why?
|
| Surveys and Questionnaires | 5 | 2015 | 2593 | 0.170 |
Why?
|
| Decision Making | 1 | 2005 | 661 | 0.170 |
Why?
|
| Anesthesia, Intravenous | 6 | 1993 | 35 | 0.170 |
Why?
|
| Propofol | 6 | 1993 | 91 | 0.160 |
Why?
|
| Brain | 4 | 2001 | 2268 | 0.160 |
Why?
|
| Ambulances | 1 | 2018 | 15 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2001 | 253 | 0.160 |
Why?
|
| Pain, Postoperative | 2 | 1997 | 248 | 0.150 |
Why?
|
| Infant Behavior | 1 | 1997 | 5 | 0.150 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1997 | 16 | 0.150 |
Why?
|
| Analgesia, Obstetrical | 1 | 1997 | 21 | 0.150 |
Why?
|
| Analgesia, Epidural | 1 | 1997 | 38 | 0.150 |
Why?
|
| Prostatic Neoplasms | 7 | 1997 | 1764 | 0.150 |
Why?
|
| Sex Factors | 6 | 2014 | 1063 | 0.140 |
Why?
|
| Chymopapain | 3 | 1985 | 6 | 0.140 |
Why?
|
| Ethanol | 3 | 1993 | 250 | 0.130 |
Why?
|
| Hospital Mortality | 1 | 2018 | 381 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2016 | 217 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 251 | 0.130 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 1995 | 186 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2016 | 186 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 77 | 0.130 |
Why?
|
| Follow-Up Studies | 8 | 2010 | 3655 | 0.130 |
Why?
|
| Anesthesia, Spinal | 1 | 1994 | 15 | 0.120 |
Why?
|
| Spinal Puncture | 1 | 1994 | 37 | 0.120 |
Why?
|
| Postoperative Complications | 4 | 1994 | 2285 | 0.120 |
Why?
|
| Intervertebral Disc Displacement | 2 | 1985 | 22 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 777 | 0.120 |
Why?
|
| Headache | 1 | 1994 | 72 | 0.120 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2014 | 52 | 0.120 |
Why?
|
| Hospitals | 1 | 2016 | 298 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 199 | 0.120 |
Why?
|
| Decompressive Craniectomy | 1 | 2014 | 18 | 0.120 |
Why?
|
| Dura Mater | 1 | 2014 | 44 | 0.110 |
Why?
|
| Endopeptidases | 2 | 1985 | 117 | 0.110 |
Why?
|
| Thiopental | 1 | 1993 | 15 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2016 | 333 | 0.110 |
Why?
|
| Prospective Studies | 11 | 2012 | 4271 | 0.110 |
Why?
|
| Interviews as Topic | 4 | 2014 | 333 | 0.110 |
Why?
|
| Brain Edema | 1 | 2014 | 57 | 0.110 |
Why?
|
| Prevalence | 3 | 2015 | 1248 | 0.110 |
Why?
|
| Cerebral Infarction | 1 | 2014 | 72 | 0.110 |
Why?
|
| Adolescent | 17 | 2018 | 9157 | 0.110 |
Why?
|
| Survival Analysis | 6 | 2005 | 1542 | 0.110 |
Why?
|
| Hostility | 3 | 2010 | 24 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2016 | 340 | 0.110 |
Why?
|
| Cause of Death | 2 | 2013 | 270 | 0.110 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2012 | 79 | 0.110 |
Why?
|
| Hospitals, Community | 2 | 1989 | 32 | 0.110 |
Why?
|
| Skin Temperature | 1 | 1992 | 15 | 0.110 |
Why?
|
| Sex Characteristics | 3 | 2010 | 321 | 0.110 |
Why?
|
| Aggression | 1 | 1996 | 323 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 510 | 0.100 |
Why?
|
| Body Temperature | 1 | 1992 | 125 | 0.100 |
Why?
|
| Sensation | 1 | 1992 | 47 | 0.100 |
Why?
|
| Cold Temperature | 1 | 1992 | 160 | 0.100 |
Why?
|
| Long QT Syndrome | 1 | 2012 | 36 | 0.100 |
Why?
|
| Body Surface Area | 1 | 1992 | 36 | 0.100 |
Why?
|
| Obesity, Morbid | 1 | 1994 | 230 | 0.100 |
Why?
|
| National Health Programs | 2 | 2001 | 19 | 0.100 |
Why?
|
| Socioeconomic Factors | 4 | 2010 | 577 | 0.100 |
Why?
|
| Tremor | 1 | 1991 | 22 | 0.100 |
Why?
|
| Body Temperature Regulation | 1 | 1991 | 56 | 0.100 |
Why?
|
| Lidocaine | 1 | 1991 | 64 | 0.100 |
Why?
|
| Patient Selection | 3 | 2014 | 689 | 0.100 |
Why?
|
| Affective Symptoms | 1 | 2010 | 50 | 0.090 |
Why?
|
| Proportional Hazards Models | 5 | 2005 | 858 | 0.090 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2012 | 136 | 0.090 |
Why?
|
| Product Surveillance, Postmarketing | 7 | 1993 | 38 | 0.090 |
Why?
|
| Life Change Events | 1 | 2010 | 48 | 0.090 |
Why?
|
| Chicago | 5 | 2018 | 1411 | 0.090 |
Why?
|
| Regression Analysis | 3 | 2004 | 594 | 0.090 |
Why?
|
| Models, Cardiovascular | 1 | 2010 | 104 | 0.090 |
Why?
|
| Stress, Psychological | 3 | 2010 | 321 | 0.090 |
Why?
|
| Hip Fractures | 2 | 2001 | 46 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 1945 | 0.090 |
Why?
|
| Information Systems | 1 | 1989 | 29 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2010 | 893 | 0.090 |
Why?
|
| Drug Administration Schedule | 5 | 2005 | 902 | 0.090 |
Why?
|
| Anesthesia Recovery Period | 3 | 1993 | 56 | 0.080 |
Why?
|
| Treatment Outcome | 8 | 2016 | 8178 | 0.080 |
Why?
|
| Kidney Calculi | 2 | 2003 | 340 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2010 | 207 | 0.080 |
Why?
|
| Cholesterol, VLDL | 1 | 2008 | 14 | 0.080 |
Why?
|
| Receptors, LDL | 1 | 2008 | 54 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 1057 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2005 | 2746 | 0.080 |
Why?
|
| Drug Combinations | 4 | 2012 | 203 | 0.080 |
Why?
|
| Heart Diseases | 2 | 2005 | 297 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 352 | 0.080 |
Why?
|
| Health Status Indicators | 2 | 2003 | 104 | 0.080 |
Why?
|
| Craniocerebral Trauma | 1 | 1988 | 54 | 0.080 |
Why?
|
| Attitude to Health | 2 | 2009 | 221 | 0.080 |
Why?
|
| Aortic Diseases | 1 | 2008 | 99 | 0.080 |
Why?
|
| Heart Rate | 1 | 2010 | 492 | 0.080 |
Why?
|
| Cervical Vertebrae | 1 | 1988 | 81 | 0.080 |
Why?
|
| Pregnancy | 5 | 1997 | 2996 | 0.070 |
Why?
|
| Pain | 2 | 2006 | 401 | 0.070 |
Why?
|
| Preoperative Care | 4 | 1994 | 398 | 0.070 |
Why?
|
| Anaphylaxis | 3 | 1998 | 33 | 0.070 |
Why?
|
| Risk Assessment | 5 | 2013 | 2286 | 0.070 |
Why?
|
| Motor Activity | 1 | 2009 | 328 | 0.070 |
Why?
|
| Retrospective Studies | 8 | 2016 | 8893 | 0.070 |
Why?
|
| Mesalamine | 2 | 2004 | 87 | 0.070 |
Why?
|
| Chromatography, Liquid | 1 | 2006 | 106 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 2 | 2004 | 270 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 193 | 0.070 |
Why?
|
| Desipramine | 2 | 1995 | 9 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2005 | 49 | 0.070 |
Why?
|
| Anesthesiology | 3 | 2000 | 160 | 0.070 |
Why?
|
| Mexican Americans | 1 | 2005 | 66 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2008 | 255 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 1999 | 1142 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2004 | 242 | 0.060 |
Why?
|
| Affect | 2 | 2006 | 387 | 0.060 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 2005 | 24 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2005 | 902 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2005 | 360 | 0.060 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2005 | 57 | 0.060 |
Why?
|
| Overweight | 1 | 2005 | 118 | 0.060 |
Why?
|
| Psychomotor Performance | 3 | 1993 | 497 | 0.060 |
Why?
|
| Endpoint Determination | 1 | 2004 | 60 | 0.060 |
Why?
|
| Mercaptopurine | 1 | 2004 | 53 | 0.060 |
Why?
|
| Life Expectancy | 2 | 2003 | 87 | 0.060 |
Why?
|
| Muscle Weakness | 1 | 2004 | 60 | 0.060 |
Why?
|
| Reference Values | 1 | 2005 | 665 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2005 | 261 | 0.060 |
Why?
|
| Electromyography | 1 | 2004 | 193 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 2 | 1999 | 205 | 0.060 |
Why?
|
| Sciatica | 1 | 1983 | 4 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2012 | 2837 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2005 | 278 | 0.060 |
Why?
|
| General Surgery | 2 | 1999 | 235 | 0.060 |
Why?
|
| Prognosis | 3 | 2005 | 3750 | 0.050 |
Why?
|
| Prostatectomy | 2 | 1997 | 476 | 0.050 |
Why?
|
| Drug Interactions | 4 | 2004 | 248 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2005 | 837 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 1983 | 111 | 0.050 |
Why?
|
| Anesthesia, General | 2 | 2001 | 116 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 995 | 0.050 |
Why?
|
| Reye Syndrome | 1 | 1982 | 22 | 0.050 |
Why?
|
| Lactates | 1 | 1982 | 37 | 0.050 |
Why?
|
| Behavior, Animal | 1 | 2005 | 376 | 0.050 |
Why?
|
| Cartilage, Articular | 1 | 2002 | 69 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 1709 | 0.050 |
Why?
|
| Herpes Labialis | 1 | 2001 | 9 | 0.050 |
Why?
|
| New England | 1 | 2001 | 10 | 0.050 |
Why?
|
| Fatty Alcohols | 1 | 2001 | 10 | 0.050 |
Why?
|
| Medical History Taking | 2 | 1992 | 81 | 0.050 |
Why?
|
| Portugal | 1 | 2001 | 26 | 0.050 |
Why?
|
| Midazolam | 2 | 1991 | 48 | 0.050 |
Why?
|
| Research Design | 1 | 2005 | 594 | 0.050 |
Why?
|
| Heart | 2 | 1995 | 572 | 0.050 |
Why?
|
| Anesthesia | 2 | 1993 | 169 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2003 | 294 | 0.050 |
Why?
|
| Pain Measurement | 3 | 2006 | 329 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2001 | 111 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2003 | 319 | 0.050 |
Why?
|
| Spinal Fractures | 1 | 2001 | 76 | 0.050 |
Why?
|
| Electroencephalography | 3 | 2001 | 741 | 0.050 |
Why?
|
| School Health Services | 1 | 1980 | 15 | 0.050 |
Why?
|
| Awareness | 1 | 2001 | 89 | 0.050 |
Why?
|
| Proctitis | 1 | 2000 | 12 | 0.050 |
Why?
|
| Critical Care | 2 | 2014 | 378 | 0.050 |
Why?
|
| Bupivacaine | 2 | 2002 | 45 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 1843 | 0.040 |
Why?
|
| Homicide | 2 | 1977 | 43 | 0.040 |
Why?
|
| Echocardiography | 3 | 1994 | 933 | 0.040 |
Why?
|
| Random Allocation | 4 | 1995 | 329 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 1997 | 2445 | 0.040 |
Why?
|
| Geographic Mapping | 1 | 2018 | 12 | 0.040 |
Why?
|
| Writing | 1 | 1999 | 28 | 0.040 |
Why?
|
| Probability | 4 | 1992 | 356 | 0.040 |
Why?
|
| Quality of Life | 2 | 2006 | 1649 | 0.040 |
Why?
|
| Kidney | 1 | 2003 | 1145 | 0.040 |
Why?
|
| Vancomycin | 1 | 1998 | 73 | 0.040 |
Why?
|
| Mastectomy | 1 | 2000 | 245 | 0.040 |
Why?
|
| Frontal Lobe | 2 | 1996 | 131 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2018 | 129 | 0.040 |
Why?
|
| Child | 5 | 2016 | 7089 | 0.040 |
Why?
|
| Depression, Chemical | 1 | 1997 | 28 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 1998 | 146 | 0.040 |
Why?
|
| Meperidine | 1 | 1997 | 13 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2018 | 132 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2014 | 157 | 0.040 |
Why?
|
| Milk, Human | 1 | 1997 | 44 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2001 | 515 | 0.040 |
Why?
|
| Monitoring, Physiologic | 2 | 2014 | 266 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 1997 | 119 | 0.040 |
Why?
|
| Injections, Intravenous | 3 | 1992 | 241 | 0.040 |
Why?
|
| Survival Rate | 2 | 2003 | 1883 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2001 | 482 | 0.040 |
Why?
|
| Rage | 1 | 1996 | 1 | 0.040 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 1995 | 75 | 0.040 |
Why?
|
| Dangerous Behavior | 1 | 1996 | 4 | 0.040 |
Why?
|
| Irritable Mood | 1 | 1996 | 10 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 2 | 1994 | 86 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 1998 | 194 | 0.040 |
Why?
|
| Glutamine | 1 | 1997 | 79 | 0.040 |
Why?
|
| Carbamazepine | 1 | 1996 | 9 | 0.040 |
Why?
|
| Incidence | 3 | 1998 | 1592 | 0.030 |
Why?
|
| Periodicals as Topic | 1 | 1999 | 168 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2016 | 65 | 0.030 |
Why?
|
| Basal Ganglia | 1 | 1996 | 45 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 1997 | 114 | 0.030 |
Why?
|
| Eye Diseases | 1 | 1996 | 58 | 0.030 |
Why?
|
| Anesthetics | 1 | 1996 | 53 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2000 | 235 | 0.030 |
Why?
|
| Graft Survival | 1 | 2000 | 916 | 0.030 |
Why?
|
| Endothelins | 1 | 1995 | 26 | 0.030 |
Why?
|
| Risk-Taking | 1 | 1977 | 155 | 0.030 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1995 | 21 | 0.030 |
Why?
|
| Functional Laterality | 1 | 1996 | 201 | 0.030 |
Why?
|
| Young Adult | 2 | 2018 | 6218 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 1995 | 44 | 0.030 |
Why?
|
| Cryosurgery | 1 | 1995 | 52 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 2 | 1992 | 76 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 1996 | 174 | 0.030 |
Why?
|
| Seasons | 1 | 2016 | 233 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 2 | 2014 | 299 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2016 | 3678 | 0.030 |
Why?
|
| Death, Sudden | 1 | 1995 | 40 | 0.030 |
Why?
|
| Knee Injuries | 1 | 1995 | 54 | 0.030 |
Why?
|
| Suicide | 1 | 1977 | 151 | 0.030 |
Why?
|
| Radiography | 2 | 1988 | 807 | 0.030 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1995 | 139 | 0.030 |
Why?
|
| Arthroscopy | 1 | 1995 | 93 | 0.030 |
Why?
|
| Violence | 1 | 1996 | 151 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 1994 | 145 | 0.030 |
Why?
|
| Nasal Mucosa | 1 | 1994 | 191 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1995 | 195 | 0.030 |
Why?
|
| Pharmacoepidemiology | 1 | 1993 | 6 | 0.030 |
Why?
|
| Wakefulness | 1 | 2014 | 134 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 1995 | 182 | 0.030 |
Why?
|
| Nasal Polyps | 1 | 1994 | 60 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2000 | 1083 | 0.030 |
Why?
|
| Gambling | 1 | 1977 | 156 | 0.030 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2014 | 38 | 0.030 |
Why?
|
| Bradycardia | 1 | 1993 | 39 | 0.030 |
Why?
|
| Anesthesia, Inhalation | 1 | 1993 | 36 | 0.030 |
Why?
|
| Epilepsy | 1 | 1998 | 421 | 0.030 |
Why?
|
| Coronary Artery Bypass | 2 | 1992 | 235 | 0.030 |
Why?
|
| Sample Size | 1 | 2014 | 129 | 0.030 |
Why?
|
| Intracranial Pressure | 1 | 2014 | 87 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 1994 | 149 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 2000 | 723 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 374 | 0.030 |
Why?
|
| Hypotension | 1 | 1993 | 70 | 0.030 |
Why?
|
| Isoflurane | 1 | 1993 | 64 | 0.030 |
Why?
|
| Sulfonamides | 1 | 1995 | 318 | 0.030 |
Why?
|
| Hypersensitivity | 1 | 1994 | 158 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 2000 | 853 | 0.030 |
Why?
|
| Whole Blood Coagulation Time | 1 | 1992 | 7 | 0.030 |
Why?
|
| Nitrous Oxide | 1 | 1993 | 107 | 0.030 |
Why?
|
| Aprotinin | 1 | 1992 | 26 | 0.030 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1992 | 32 | 0.030 |
Why?
|
| Arousal | 1 | 1993 | 170 | 0.030 |
Why?
|
| Rhinitis | 1 | 1994 | 177 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 1992 | 51 | 0.030 |
Why?
|
| Electrocardiography | 2 | 2010 | 495 | 0.030 |
Why?
|
| Mental Disorders | 2 | 1995 | 406 | 0.030 |
Why?
|
| Body Constitution | 1 | 1992 | 26 | 0.030 |
Why?
|
| Albumins | 1 | 1992 | 130 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 1993 | 133 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 1992 | 48 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 1997 | 804 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1992 | 70 | 0.030 |
Why?
|
| Registries | 1 | 1996 | 759 | 0.030 |
Why?
|
| Oxygen | 3 | 2010 | 745 | 0.030 |
Why?
|
| Thrombelastography | 1 | 1992 | 47 | 0.030 |
Why?
|
| Calibration | 1 | 1992 | 102 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 1996 | 1851 | 0.020 |
Why?
|
| Injections, Epidural | 1 | 1991 | 6 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 214 | 0.020 |
Why?
|
| Body Height | 1 | 1992 | 100 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 1992 | 115 | 0.020 |
Why?
|
| Fentanyl | 1 | 1991 | 67 | 0.020 |
Why?
|
| Cortical Spreading Depression | 1 | 1991 | 21 | 0.020 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2011 | 12 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1991 | 59 | 0.020 |
Why?
|
| Creatinine | 2 | 2003 | 295 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 1992 | 252 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 866 | 0.020 |
Why?
|
| Postpartum Period | 1 | 1992 | 143 | 0.020 |
Why?
|
| Remission Induction | 2 | 2004 | 735 | 0.020 |
Why?
|
| Cardiovascular Diseases | 2 | 2010 | 707 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 1992 | 317 | 0.020 |
Why?
|
| Body Weight | 1 | 1992 | 455 | 0.020 |
Why?
|
| Weight Loss | 1 | 1992 | 225 | 0.020 |
Why?
|
| Learning | 1 | 1993 | 283 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 3117 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 1989 | 27 | 0.020 |
Why?
|
| Death | 1 | 2010 | 84 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 865 | 0.020 |
Why?
|
| Podophyllotoxin | 1 | 1989 | 10 | 0.020 |
Why?
|
| Condylomata Acuminata | 1 | 1989 | 15 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1992 | 333 | 0.020 |
Why?
|
| Penile Diseases | 1 | 1989 | 8 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 491 | 0.020 |
Why?
|
| Self Administration | 1 | 1989 | 72 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1995 | 1352 | 0.020 |
Why?
|
| Somatomedins | 1 | 1989 | 28 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 1989 | 33 | 0.020 |
Why?
|
| Social Identification | 1 | 2009 | 26 | 0.020 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 15 | 0.020 |
Why?
|
| Attention | 1 | 1993 | 390 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 1989 | 54 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2009 | 109 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2008 | 27 | 0.020 |
Why?
|
| Demography | 1 | 1989 | 181 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1989 | 147 | 0.020 |
Why?
|
| Pregnancy in Diabetics | 1 | 1989 | 38 | 0.020 |
Why?
|
| Injections | 2 | 1992 | 115 | 0.020 |
Why?
|
| Acute Disease | 2 | 2001 | 838 | 0.020 |
Why?
|
| Cognition | 1 | 1993 | 579 | 0.020 |
Why?
|
| Health Behavior | 1 | 2010 | 183 | 0.020 |
Why?
|
| Fractures, Closed | 1 | 1988 | 9 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1868 | 0.020 |
Why?
|
| Postoperative Period | 2 | 2004 | 306 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 1992 | 602 | 0.020 |
Why?
|
| Rats | 3 | 2005 | 4041 | 0.020 |
Why?
|
| Joint Dislocations | 1 | 1988 | 27 | 0.020 |
Why?
|
| Triglycerides | 1 | 2008 | 232 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2008 | 166 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2008 | 223 | 0.020 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1988 | 94 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1992 | 597 | 0.020 |
Why?
|
| Contrast Media | 1 | 1992 | 1088 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1992 | 473 | 0.020 |
Why?
|
| Students, Medical | 1 | 1992 | 418 | 0.020 |
Why?
|
| Rorschach Test | 2 | 1977 | 3 | 0.020 |
Why?
|
| Administration, Topical | 2 | 2001 | 96 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 2980 | 0.020 |
Why?
|
| Animals | 6 | 2008 | 27233 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2000 | 1213 | 0.020 |
Why?
|
| Social Behavior | 1 | 2008 | 297 | 0.020 |
Why?
|
| Iothalamate Meglumine | 1 | 1985 | 5 | 0.020 |
Why?
|
| Spasm | 1 | 1985 | 17 | 0.020 |
Why?
|
| Apomorphine | 1 | 2005 | 10 | 0.020 |
Why?
|
| Dopamine D2 Receptor Antagonists | 1 | 2005 | 7 | 0.020 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2005 | 15 | 0.020 |
Why?
|
| Amphetamines | 1 | 2005 | 18 | 0.020 |
Why?
|
| Haloperidol | 1 | 2005 | 30 | 0.020 |
Why?
|
| Dopamine Agonists | 1 | 2005 | 27 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2008 | 948 | 0.020 |
Why?
|
| Dopamine Antagonists | 1 | 2005 | 35 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2005 | 35 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2005 | 101 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2004 | 5 | 0.020 |
Why?
|
| Fluorobenzenes | 1 | 2005 | 33 | 0.020 |
Why?
|
| Indans | 1 | 2005 | 35 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 120 | 0.020 |
Why?
|
| Discrimination Learning | 1 | 2005 | 63 | 0.020 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2005 | 44 | 0.020 |
Why?
|
| Stroke | 1 | 2014 | 980 | 0.020 |
Why?
|
| Quinolines | 1 | 2005 | 91 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2004 | 52 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2004 | 87 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 2004 | 154 | 0.010 |
Why?
|
| Confidence Intervals | 2 | 1995 | 226 | 0.010 |
Why?
|
| Amphetamine | 1 | 2005 | 101 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 2 | 1997 | 358 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2004 | 163 | 0.010 |
Why?
|
| Piperidines | 1 | 2005 | 163 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 1988 | 0.010 |
Why?
|
| Cues | 1 | 2005 | 177 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1989 | 562 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1983 | 138 | 0.010 |
Why?
|
| HIV Infections | 1 | 1992 | 829 | 0.010 |
Why?
|
| Hallucinogens | 1 | 2005 | 77 | 0.010 |
Why?
|
| Recurrence | 2 | 2001 | 1168 | 0.010 |
Why?
|
| Psychotic Disorders | 1 | 2005 | 192 | 0.010 |
Why?
|
| Risk | 2 | 1995 | 660 | 0.010 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2004 | 124 | 0.010 |
Why?
|
| Sulfur Oxides | 1 | 2002 | 4 | 0.010 |
Why?
|
| Knee | 1 | 2002 | 17 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2002 | 87 | 0.010 |
Why?
|
| Pyruvates | 1 | 1982 | 11 | 0.010 |
Why?
|
| Pyruvate Carboxylase | 1 | 1982 | 6 | 0.010 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 1982 | 13 | 0.010 |
Why?
|
| Ammonia | 1 | 1982 | 38 | 0.010 |
Why?
|
| Acidosis | 1 | 1982 | 55 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2005 | 1237 | 0.010 |
Why?
|
| Femur Neck | 1 | 2001 | 41 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2002 | 76 | 0.010 |
Why?
|
| Ointments | 1 | 2001 | 12 | 0.010 |
Why?
|
| Coma | 1 | 1982 | 45 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 3202 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 2346 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 646 | 0.010 |
Why?
|
| Cardiopulmonary Bypass | 2 | 1992 | 158 | 0.010 |
Why?
|
| Denmark | 1 | 1980 | 17 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 995 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2001 | 155 | 0.010 |
Why?
|
| Bone Density | 1 | 2001 | 209 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2001 | 123 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1989 | 1167 | 0.010 |
Why?
|
| Histocompatibility | 1 | 2000 | 66 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2000 | 289 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2000 | 295 | 0.010 |
Why?
|
| Chymases | 1 | 1998 | 11 | 0.010 |
Why?
|
| Tryptases | 1 | 1998 | 12 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2000 | 471 | 0.010 |
Why?
|
| Quality Control | 1 | 1999 | 116 | 0.010 |
Why?
|
| Mass Screening | 2 | 1993 | 631 | 0.010 |
Why?
|
| Histamine | 1 | 1998 | 126 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2000 | 219 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 1998 | 5 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1982 | 840 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2000 | 358 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1998 | 222 | 0.010 |
Why?
|
| Geography | 1 | 1998 | 228 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2000 | 258 | 0.010 |
Why?
|
| Diazooxonorleucine | 1 | 1997 | 5 | 0.010 |
Why?
|
| Space Flight | 1 | 1977 | 7 | 0.010 |
Why?
|
| Conjunctivitis | 1 | 1996 | 6 | 0.010 |
Why?
|
| Oxidants | 1 | 1997 | 86 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1998 | 193 | 0.010 |
Why?
|
| Corneal Diseases | 1 | 1996 | 33 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1997 | 208 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 1995 | 18 | 0.010 |
Why?
|
| Europe | 1 | 1996 | 314 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 1995 | 107 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 1995 | 75 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1995 | 105 | 0.010 |
Why?
|
| Vasodilation | 1 | 1995 | 94 | 0.010 |
Why?
|
| Injections, Intra-Articular | 1 | 1995 | 27 | 0.010 |
Why?
|
| Carotid Artery, Internal | 1 | 1995 | 70 | 0.010 |
Why?
|
| Poisson Distribution | 1 | 1995 | 51 | 0.010 |
Why?
|
| Radioallergosorbent Test | 1 | 1994 | 8 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1995 | 199 | 0.010 |
Why?
|
| Radionuclide Ventriculography | 1 | 1994 | 3 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 1994 | 5 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1995 | 198 | 0.010 |
Why?
|
| Medicare | 1 | 1998 | 420 | 0.010 |
Why?
|
| Drug Utilization | 1 | 1995 | 65 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 11710 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2000 | 661 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 1995 | 144 | 0.010 |
Why?
|
| Bias | 1 | 1994 | 130 | 0.010 |
Why?
|
| Biomarkers | 1 | 2000 | 1759 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1994 | 238 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1998 | 2019 | 0.010 |
Why?
|
| San Francisco | 1 | 1992 | 23 | 0.010 |
Why?
|
| Diatomaceous Earth | 1 | 1992 | 3 | 0.010 |
Why?
|
| Kaolin | 1 | 1992 | 9 | 0.010 |
Why?
|
| Medical Audit | 1 | 1992 | 39 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 1992 | 18 | 0.010 |
Why?
|
| New York | 1 | 1992 | 70 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1992 | 33 | 0.010 |
Why?
|
| Narcolepsy | 1 | 1992 | 9 | 0.010 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 1992 | 5 | 0.010 |
Why?
|
| Sleep, REM | 1 | 1992 | 51 | 0.010 |
Why?
|
| Hepatitis B Vaccines | 1 | 1992 | 15 | 0.010 |
Why?
|
| Cost Savings | 1 | 1992 | 69 | 0.010 |
Why?
|
| Attitude to Computers | 1 | 1992 | 12 | 0.010 |
Why?
|
| Preventive Medicine | 1 | 1992 | 17 | 0.010 |
Why?
|
| Cell Line | 1 | 1997 | 2498 | 0.010 |
Why?
|
| Particle Size | 1 | 1992 | 123 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 108 | 0.010 |
Why?
|
| Hematocrit | 1 | 1992 | 68 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1992 | 195 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1992 | 63 | 0.010 |
Why?
|
| Medical Records | 1 | 1992 | 121 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 1992 | 35 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1992 | 128 | 0.010 |
Why?
|
| Health Services Research | 1 | 1992 | 137 | 0.010 |
Why?
|
| Physical Examination | 1 | 1993 | 148 | 0.010 |
Why?
|
| Hepatitis B | 1 | 1992 | 76 | 0.010 |
Why?
|
| Heparin | 1 | 1992 | 184 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 1991 | 87 | 0.010 |
Why?
|
| Computers | 1 | 1991 | 112 | 0.010 |
Why?
|
| Heart Valve Prosthesis | 1 | 1992 | 97 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1992 | 202 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1997 | 1983 | 0.010 |
Why?
|
| Dogs | 1 | 1992 | 704 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 312 | 0.010 |
Why?
|
| Drainage | 1 | 1992 | 158 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 1992 | 116 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1991 | 306 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1997 | 2009 | 0.010 |
Why?
|
| Heart Atria | 1 | 1992 | 281 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1991 | 202 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 1991 | 117 | 0.010 |
Why?
|
| Language | 1 | 1991 | 154 | 0.010 |
Why?
|
| DNA Probes | 1 | 1989 | 77 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 1989 | 73 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1989 | 156 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1991 | 274 | 0.010 |
Why?
|
| Schizophrenia | 1 | 1992 | 477 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1992 | 1588 | 0.000 |
Why?
|
| Heart Ventricles | 1 | 1992 | 779 | 0.000 |
Why?
|
| Gene Frequency | 1 | 1989 | 684 | 0.000 |
Why?
|
| Anesthesia, Local | 1 | 1985 | 27 | 0.000 |
Why?
|
| Histamine H1 Antagonists | 1 | 1985 | 40 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1989 | 1077 | 0.000 |
Why?
|
| Sympathetic Nervous System | 1 | 1985 | 94 | 0.000 |
Why?
|
| Genotype | 1 | 1989 | 1867 | 0.000 |
Why?
|
| Models, Genetic | 1 | 1989 | 942 | 0.000 |
Why?
|
| Prisoners | 1 | 1975 | 44 | 0.000 |
Why?
|